A new player aiming to redefine the standard of care for reflux treatment has secured fresh capital. N-Zyme Biomedical Inc., which is developing what it calls the first pepsin inhibitor for the condition, announced it has raised $4.6M in Series A funding.
This investment will accelerate N-Zyme Biomedical's mission to bring its novel therapeutic to market. The company's focus on a pepsin inhibitor represents a distinct approach in the reflux landscape, positioning it to potentially shift existing treatment paradigms and offer a new option for patients.
.png&w=3840&q=75)
.png&w=3840&q=75)
